Imagine a world where the human heart, once damaged, could heal itself, offering a new lease of life to those affected by heart attacks or heart failure. This incredible possibility is now a step closer to reality, thanks to a groundbreaking discovery by Dr. Hina Chaudhry and her team at Mount Sinai.
The Power of a Single Gene
A naturally occurring gene, Cyclin A2 (CCNA2), holds the key to this potential revolution in heart health. This gene, which is inactive in humans after birth, can be reactivated to create new, functioning heart cells, offering a natural repair mechanism for injured hearts.
The study, published in Nature Portfolio Journals Regenerative Medicine, is a significant milestone in cardiovascular research. It builds on Dr. Chaudhry's previous work, where her team successfully regenerated the heart of a large mammal (pig) after a heart attack by reactivating CCNA2.
Bridging the Gap to Human Hearts
But here's where it gets controversial: the new study provides evidence that a human-compatible viral vector can safely trigger cell division in adult human heart cells. This translational bridge is a critical step, demonstrating the potential for this approach to be applied to human hearts.
Dr. Chaudhry explains, "Heart disease is a global concern, yet adult human heart muscle cells stop dividing after birth. Our work shows that even middle-aged adult human heart cells can be encouraged to divide and create new, functional cells. This shifts the focus from managing symptoms to actively repairing the heart."
Understanding the Process
When a heart attack or heart failure occurs, heart muscle cells are lost, and the heart cannot replace them naturally. Dr. Chaudhry's team aimed to reactivate the heart's inherent ability to regenerate by focusing on CCNA2, a gene that is normally silenced after birth.
The research team developed a replication-deficient human-compatible virus carrying the CCNA2 gene, which was delivered to heart muscle cells. The therapy was tested on living adult human heart cells from healthy donors, and the results were remarkable.
Results and Implications
Researchers analyzed heart cells with CCNA2 using time-lapse imaging and observed successful cell division while maintaining normal structure and function. Specifically, cells from donors aged 41 and 55 responded to Cyclin A2 therapy, dividing and contributing to heart repair. Cells from a 21-year-old donor, however, showed no change, aligning with previous studies suggesting younger hearts have inherent regenerative potential.
Importantly, the daughter cells retained their structural proteins and normal calcium activity, indicating functional heart cells. CCNA2 helps heart cells temporarily "turn back the clock," reactivating growth genes to facilitate division and heart repair without causing harmful thickening of heart tissue.
The Road Ahead
Dr. Chaudhry's work is a culmination of nearly two decades of dedication. She and her team aim to deliver a therapy that empowers the heart to heal itself, reducing the reliance on transplants or mechanical devices. The next step is seeking FDA approval to initiate clinical trials of CCNA2 therapy for patients with heart disease.
This study was supported by the National Institutes of Health and the New York Stem Cell Foundation Board. For more information on this groundbreaking technology, contact Mount Sinai Innovation Partners.
Mount Sinai, a world leader in cardiology and heart surgery, consistently ranks highly in various national and global rankings. Their commitment to advancing medicine and health through research and discovery is evident in their comprehensive health care solutions, leveraging innovative approaches while prioritizing patient needs.
And this is the part most people miss: the potential for a natural, less invasive treatment for heart disease. What do you think? Could this be the future of heart health? Share your thoughts in the comments!
